Thursday 2 September 2021

BioLargo Launches PFAS Testing and Treatment System Selection Program

Westminster, CA – September 2, 2021 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, announced that it has launched a new service offering to test customer water to determine PFAS contamination levels and advise on appropriate treatment equipment options to meet federal, state and local regulatory requirements. The program offers peace of mind and proof of concept to customers who need PFAS water treatment solutions in the face of an uncertain and rapidly evolving technological and regulatory landscape.

Per- and polyfluoroalkyl substances (PFAS) are man-made chemicals that contaminate drinking water in thousands of sites in the United States. The Federal government, and many state governments, are tightening regulations due to mounting evidence about the impacts of PFAS chemicals on human health and their ubiquity in water throughout the developed world. Learn more at

BioLargo’s new PFAS Testing Program offers customers timely, accurate, and reliable testing of their water to determine, quantify, and qualify their PFAS contamination problem. Once contamination and water chemistry are characterized, BioLargo selects and optimizes appropriate water treatment equipment from a menu of different technologies that addresses the customer’s specific water chemistry and PFAS contamination makeup. The company then offers on-site piloting of the company’s own PFAS water treatment technology (the Aqueous Electrostatic Concentrator, or AEC). The AEC is a low-cost, low-waste, and sustainable solution for removing PFAS from water.

Customers can reach out to BioLargo engineers to schedule testing at  

Randall Moore, President of BioLargo’s engineering division said, “With the launch of this new program, our engineers will be able to better serve municipalities that are struggling with having to close water wells due to PFAS contamination. Our AEC system reduces treatment costs because it generates only a fraction of the PFAS-laden waste compared to other treatment technologies like carbon filtration or ion exchange. No two water sources have the same underlying chemistry, and there are over 4,500 different PFAS compounds that can contaminate water. Thus, it is crucial to optimize treatment processes for each situation.”


About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. See our website at

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.


Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.


No comments:

Post a Comment